Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 197
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3165
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 597
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 511
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 317
Function: require_once
98%
921
2 minutes
20
Between 2020 and 2022 in the United Kingdom (UK), there were 45 maternal deaths from venous thromboembolism (VTE), out of more than 2 million maternities. This occurred despite extensive risk assessment and prescribing of low molecular weight heparin (LMWH) thromboprophylaxis, alongside clinicians' overestimate of risk and commitment to the cause. Whilst every maternal death is a tragedy, the challenge ahead is immense-to identify, in an efficient and consistent way, those few women at risk of life-threatening thrombosis, and then minimise that risk with a cost-effective therapy that is acceptable to pregnant and postpartum women, and does not do more harm than good. We propose a way forward.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12315063 | PMC |
http://dx.doi.org/10.1111/1471-0528.18229 | DOI Listing |